background image

Paid Clinical Trials Hillsboro

Discover 942 paid clinical trials in Hillsboro, Oregon. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2
Active & Responsive

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for
Breast Cancer
Location: 120 recruiting locations
Sponsor: Stemline Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06492616

Phase3, Recruiting
Active & Responsive

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

for
Breast Neoplasms, Breast Cancer
Location: 8 recruiting locations
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06797635

Phase2, Recruiting
Active & Responsive

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

for
Colorectal Neoplasms
Location: 63 recruiting locations
Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All

Age: 18+

Code: NCT05253651

Phase3, Recruiting
Active & Responsive

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

for
Cervical Cancer,
Location: 13 recruiting locations
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT04895709

Phase1, Phase2, Recruiting
Active & Responsive

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

for
Metastatic Castration-resistant Prostate Cancer
Location: 40 recruiting locations
Sponsor: Celgene

Sex: Male

Age: 18+

Code: NCT06764485

Phase3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)

for
Alzheimer Disease, Dementia
Location: 29 recruiting locations
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 55 - 70+

Code: NCT06721156

Phase2, Recruiting
Active & Responsive

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

for
Small Cell Lung Cancer
Location: 8 recruiting locations
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06780137

Phase1, Phase2, Recruiting
Active & Responsive

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

for
Primary Central Nervous System Lymphoma
Location: 5 recruiting locations
Sponsor: Providence Health & Services

Sex: All

Age: 18+

Code: NCT06175000

Phase2, Recruiting
Active & Responsive

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

for
Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation,
Location: 11 recruiting locations
Sponsor: University of California, San Francisco

Sex: All

Age: 13 - 39

Code: NCT03749187

Phase1, Recruiting
Active & Responsive

Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study

for
Prostate Carcinoma
Location: 7 recruiting locations
Sponsor: University of Washington

Sex: Male

Age: 40+

Code: NCT04472338

Recruiting